Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage

Therapeutic Advances in Neurological Disorders

Volumn 5, Issue 1, 2012, Pages 43-56

  Moussouttas, Michael ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

antithrombotic; challenges; controversies; hematoma expansion; intracerebral hemorrhage; medical management; primary; review

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; ARGATROBAN; CHARCOAL; COBALAMIN; DABIGATRAN; DEXAMETHASONE; FONDAPARINUX; FRESH FROZEN PLASMA; GLYCEROL; HEPARIN; HEPARINOID; HIRUDIN; MANNITOL; NICARDIPINE; PLACEBO; PROTAMINE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; WARFARIN;

BRAIN EDEMA; BRAIN HEMORRHAGE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; ENCEPHALITIS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMATOMA; HEMOPHILIA; HUMAN; HYDROCEPHALUS; HYPERGLYCEMIA; HYPERTENSION; HYPERVOLEMIA; INFECTION; MORTALITY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

EID: 84858234693     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285611422267     Document Type: Review

References (110)

1. Almandoz D. Yoo A. Stone M. Schaefer P. Oleinik A. Brouwers H. et al (2010) The spot sign score in primary intracerebral hemorrhage identifies patients at highest risk of in-hospital mortality and poor outcome among survivors. Stroke 41: 54–60.
2. Anderson C. Huang Y. Arima H. Heeley E. Skulina C. Parsons M. et al (2010) Effects of early intensive blood pressure lowering treatment on the growth of hematoma and peerihematomal edema in acute intracerebral hemorrhage. Stroke 41: 307–312.
3. Anderson C. Huang Y. Wang J. Arima H. Neal B. Peng B. et al (2008) Acute Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT). Lancet Neurology 7: 391–399.
4. Arima H. Wang J. Huang Y. Heeley E. Skulina C. Parsons M. et al (2009) Significance of perihematomal edema in acute intracerebral hemorrhage – the INTERACT Trial. Neurology 73: 1963–1968.
5. ATACH Investigators. (2010) Antihypertensive treatment of acute cerebral hemorrhage. Crit Care Med 38: 637–648.
6. Bailey R. Hart R. Benavente O. Pearce L. (2001) Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology 56: 773–777.
7. Barras C. Tress B. Christensen S. MacGregor L. Collins M. Desmond P. et al (2009) Density and shape as CT predictors of intracerebral hemorrhage growth. Stroke 40: 1325–1331.
8. Berlex (2004) Lepirudin. Montville, NJ; USA.
9. Bershad E. Suarez J. (2010) Prothrombin complex concentrates for oral anticoagulant therapy related intracranial hemorrhge – a review of the literature. Neurocrit Care 12: 403–414.
10. Boehringer Ingelheim (2010) Dabigatran etexilate. Ingelheim, Germany.
11. Breet N. VanWerkum J. Bouman H. Kelder J. Ruven H. Bal E. et al (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303: 754–762.
12. Bristol Myers Squibb (2007) Apixaban. New York, NY; USA.
13. Broderick J. Connolly S. Feldmann E. Hanley D. Kase C. Krieger D. et al (2007 a) Guidelines for the management of spontaneous intracerebral hemorrhage in adults. Stroke 38: e391–e413.
14. Broderick J. Diringer M. Hill M. Brun N. Mayer S. Steiner T. et al (2007 b) Determinants of Intracerebral hemorrhage growth – an exploratory analysis. Stroke 38: 1072–1075.
15. Brott T. Broderick J. Kothari R. Barsan W. Tomsick T. Sauerbeck L. et al (1997) Early hemorrhge growth in patients with intracerebral hemorrhage. Stroke 28: 1–5.
16. Carhuapoma J. Wang P. Beauchamp N. Keyl P. Hanley D. Barker P. (2000) Diffusion-weighted MRI and proton MR spectroscopic imaging in the study of secondary neuronal injury after intracerebral hemorrhage. Stroke 31: 726–732.
17. Cleland J. Coletta A. Buga L. Antony R. Pellicori P. Freemantle N. et al (2011) Clinical trials update from the American Heart Association Meeting 2010. Eur J Heart Fail 13: 460–465.
18. Connolly S. Eikelboom J. Joyner C. Diener H. Hart R. Golitsyn S. et al (2011) Apixaban in patients with atrial fibrillarion. N Eng J Med 364: 806–817.
19. Connolly S. Ezekowitz M. Yusuf S. Eikelboom J. Oldgren J. Parekh A. et al (2010) Dabigatran versus warfarin in patients with atrial fibrillation. N Eng J Med 361: 1139–1151.
20. Counsell C. Boonyakarnukul S. Dennis M. Sandercock P. Bamford J. Burn J. et al (1995) Primary intracerebral hemorrhage in the Oxfordshire Community Stroke Project. Cerebrovasc Dis 5: 26–34.
21. Creutzfeldt C. Weinstein J. Longstreth W. Becker K. McPharlin T. Tirschwell D. (2009) Prior antiplatelet therapy, platelet infusion therapy, and outcome after intracerebral hemorrhage. J Stroke Cerebrovasc Dis 18: 221–228.
22. Cucchiara B. Messe S. Sansing L. Kasner S. Lyden P. (2008) Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 39: 2993–2996.
23. Davis S. Broderick J. Hennerici M. Brun N. Diringer M. Mayer S. et al (2006) Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 66: 1175–1181.
24. Dickneite G. (2007) Prothrombin complex concentrate versus recombinant factor viia for reversal of coumarin anticoagulation. Thromb Res 119: 643–651.
25. Dowlatshahi D. Demchuk A. Flaherty M. Ali M. Lyden P. Smith E. (2011) Defining hematoma expansion in intracerebral hemorrhge – relationship with patient outcomes. Neurology 76: 1238–1244.
26. Ducret A. Hickman Z. Zacharia B. Gorobelny B. de Rosa P. Landes E. et al (2010) Impact of platelet transfusion on hematoma expansion in patients receiving antiplatelet agents before intracerebral hemorrhage. Neurol Res 32: 706–710.
27. Eckman M. Rosand J. Knudsen K. Singer D. Greenberg S. (2003) Can patients be anticoagulated after intracerebral hemorrhage - a decision analysis. Stroke 34: 1710–1716.
28. Fan Y. Zhang L. Lam W. Mok V. Wong K. (2003) Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. Stroke 34: 2459–2462.
29. Fiore L. Scola M. Cantillon C. Brophy M. (2001) Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 11: 175–183.
30. Flibotte J. Hagan N. O'Donnell J. Greenberg S. Rosand J. (2004) Warfarin, Hematoma Expansion, and Outcome of Intracerebral Hemorrhage. Neurology 63: 1059–1064.
31. Foerch C. Sitzer M. Steinmetz H. Neumann-Haefelin T. (2006) Pretreatment with antiplatelet agents is not independently associated with unfavorable outcome in intracerebral hemorrhage. Stroke 37: 2165–2167.
32. Gebel J. Jauch E. Brott T. Khoury J. Sauerbeck L. Salisbury S. et al (2002) Relative edema volume is a predictor of outcome in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 33: 2636–2641.
33. Gebel J. Sila C. Sloan M. Granger C. Mahaffy K. Weisenberger J. et al (1998) Thrombolysis related intracranial hemorrhage. Stroke 29: 563–569.
34. Go A. Hylek E. Phillips K. Chang Y. Henault L. Selby J. et al (2001) Prevalence of diagnosed atrial fibrillation in adults. JAMA 285: 2370–2375.
35. Goldstein J. Fazen L. Snider R. Schwab K. Greenberg S. Smith E. et al (2007) Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage. Neurology 68: 889–894.
36. Hallevi H. Albright K. Aronowski J. Barreto A. Schild S. Khaja A. et al (2008) Intraventricular hemorrhage – anatomic relationships and clinical implications. Neurology 70: 848–852.
37. Hart R. Boop B. Anderson D. (1995) Oral anticoagulants and intracerebral hemorrhage. Stroke 26: 1471–1477.
38. Hemphill J. Bonovich D. Besmertis L. Manley G. Johnston C. (2001) The ICH score – a simple and reliable grading scale for intracerebral hemorrhage. Stroke 32: 891–897.
39. Hirsh J. Raschke R. (2004) Heparin and low molecular heparin – the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl): 188s–203s.
40. Hoff J. Xi G. (2003) Brain edema from intracerebral hemorrhage. Acta Neurochir 86(Suppl): 11–15.
41. Holland L. Brooks J. (2006) Toward rational fresh frozen plasma transfusion. Am J Clin Pathol 126: 133–139.
42. Huttner H. Schellinger P. Hartmann M. Kohrmann M. Juettler E. Winker J. et al (2006 a) Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy. Stroke 37: 1465–1470.
43. Huttner H. Steiner T. Hartmann M. Kohrmann M. Juettler E. Mueller S. et al (2006 b) Comparison of ABC/2 estimation technique to computer assisted planimetric analysis in warfarin related intracerebral parenchymal hemorrhage. Stroke 37: 404–408.
44. Ichikawa K. Yanagihara C. (1998) Sedimentation level in acute intracerebral hematoma in a patient receiving anticoagulation therapy – an autopsy study. Neuroradiology 40: 380–382.
45. Ishibashi A. Yokokura Y. Adachi H. (2008) Is antiplatelet therapy for the prevention of ischemic stroke associated with the prognosis of intracerebral hemorrhage?. Kurume Med J 55: 71–75.
46. Jauch E. Lindsell C. Adeoye O. Khoury J. Barsan W. Broderick J. et al (2006) Lack of evidence for an association between hemodynamic variables and hematoma growth in spontaneous intracerebral hemorrhage. Stroke 37: 2061–2065.
47. Johnson & Johnson (2009) Rivoroxaban. New Brunswick, NJ; USA.
48. Kalita J. Misra U. Ranjan P. Pradhan P. Das B. (2004) Effect of mannitol on regional CBF in patients with intracerebral hemorrhage. J Neurol Sci 224: 19–22.
49. Kim J. Kopp S. Dugan L. Diringer M. (2006) Perihematomal mitochondrial dysfunction after intracerebral hemorrhage. Stroke 37: 2457–2462.
50. Kollmar R. Schabitz W. Heiland S. Georgiadis D. Schellinger P. Bardutzky J. et al (2002) Neuroprotective effect of delayed moderate hypothermia after focal cerebral ischemia – an MRI study. Stroke 33: 1899–1904.
51. Kollmar R. Staykov D. Dorfler A. Schellinger P. Schwab S. Bardutzky J. (2010) Hypothermia reduces perihemorrhagic edema after intracerebral hemorrhage. Stroke 41: 1684–1689.
52. Kothari R. Brott T. Broderick J. Barsan W. Sauerbeck L. Zuccarello M. et al (1996) The ABCs of measuring intracerebral hemorrhage volumes. Stroke 27: 1304–1305.
53. Lacut K. Le Gal G. Seizeur R. Prat G. Mottier D. Oger E. (2007) Antiplatelet drug use preceding the onset of intracerebral hemorrhage is associated with increased mortality. Fundam Clin Pharmacol 21: 327–333.
54. Lauer A. Schlunk F. van Cott E. Steinmetz H. Lo E. Foerch C. (2011) Antiplatelt pretreatment does not increase hematoma volume in experimental intracerebral hemorrhage. J Cereb Blood Flow Metab 31: 1736–1742.
55. Lee S. Manno E. Layton K. Wijdicks E. (2006) Progression of warfarin associated intracerebral hemorrhage after INR normalization with FFP. Neurology 67: 1272–1274.
56. Leissinger C. Blatt P. Hoots W. Ewenstein B. (2008) Role of prothrombin complex concentrates in reversing warfarin anticoagulation – a review of the literature. Am J Hematol 83: 137–143.
57. Levy J. Key N. Azran M. (2010) Novel oral anticoagulants – implications in the perioperative setting. Anesthesiology 113: 726–745.
58. MacLellan C. Davies L. Fingas M. Colbourne F. (2006) The influence of hypothermia on outcome after intracerebral hemorrhage in rats. Stroke 37: 1266–1270.
59. MacLellan C. Girgis J. Colbourne F. (2004) Delayed onset of prolonged hypothermia improves outcome after intracerebral hemorrhage in rats. J Cereb Blood Flow Metab 24: 432–440.
60. Makris M. Greaves M. Phillips W. Kitchen S. Rosendaal F. Preston E. (1997) Emergency oral anticoagulant reversal – the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 77: 477–480.
61. Mayer S. Brun N. Begtrup K. Broderick J. Davis S. Diringer M. et al (2005) Recombinant activated factor VII for acute uintracerebral hemorrhage. N Eng J Med 352: 777–785.
62. Mayer S. Brun N. Begtrup K. Broderick J. Davis S. Diringer M. et al (2008) Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Eng J Med 358: 2127–2137.
63. Mayer S. Davis S. Skolnick B. Brun N. Begrrup K. Broderick J. et al (2009) Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII?. Stroke 40: 833–840.
64. Mendelow A. Gregson B. Fernandes H. Murray G. Teasdale G. Hope D. et al (2005) Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral hematomas in the International Surgical Trial in Intracerebral Hemorrhage (STICH) – a randomized trial. Lancet 365: 387–397.
65. Misra U. Kalita J. Ranjan P. Nandal S. (2005) Mannitol in intracerebral hemorrhage – a randomized controlled study. J Neurol Sci 234: 41–45.
66. Morgensetern L. Hemphill J. Anderson C. Becker K. Broderick J. Connolly S. et al (2010) Guidelines for the management of spontaneous intracerebral hemorrhage. Stroke 41: 2108–2129.
67. Moussouttas M. Malhotra R. Fernandez L. Maltenfort M. Holowecki M. Delgado J. et al (2010) Role of antiplatelet agents in hematoma expansion during the acute period of intracerebral hemorrhage. Neurocrit Care 12: 24–29.
68. Moussouttas M. Malhotra R. Fernandez L. Maltnefort M. Holowecki M. Delgado J. et al (2011) Impact of intraventricular hemorrhage upon intracerebral hematoma expansion. Neurocrit Care 14: 50–54.
69. Naidech A. Bassin S. Bernstein R. Batjer H. Alberts M. Lindholm P. et al (2009 a) Reduced platelet activity is more common than reported antiplatelet medication use in patients with intracerebral hemorrhage. Neurocrit Care 11: 307–310.
70. Naidech A. Bernstein R. Levasseur K. Bassin S. Bendok B. Batjer H. et al (2009 b) Platelet activity and outcome after intracerebral hemorrhage. Ann Neurol 65: 352–356.
71. Naidech A.M. Jovanovic B. Liebling S. Garg R.K. Bassin S.L. Bendok B.R. et al (2009 c) Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke 40: 2398–2401.
72. O'Donnell H. Rosand J. Knudsen K. Furle K. Segal A. Chiu R. et al (2000) Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Eng J Med 342: 240–245.
73. Olivot J. Miynash M. Kleinman J. Straka M. Venkatasubramanian C. Bammer R. et al (2010) MRI profile of the perihematomal region in acute intracerebral hemorrhage. Stroke 41: 2681–2683.
74. Pantazis G. Tsitsopoulos P. Mihas C. Katsiva V. Stavrianos V. Zymaris S. (2006) Early surgical treatment versus conservative management for spontaneous supratentorial intracerebral hematomas – a prospective randomized study. Surg Neurol 66: 492–501.
75. Pfizer (2007) Dalteparin sodium. New York, NY; USA.
76. Polderman K. Herold I. (2009) Therapeutic hypothermia and controlled normothermia in the intensive care unit – practical considerations, side effects and cooling methods. Crit Care Med 37: 1101–1120.
77. Poungvarin N. Bhoopat W. Viriyavejakul A. Rodprasert P. Buranasiri P. Sukondhabhant S. et al (1987) Effects of dexamethasone in primary supratentorial intracerebral hemorrhage. N Eng J Med 316: 1229–1233.
78. Qureshi A. Mendelow A. Hanley D. (2009) Intracerebral hemorrhage. Lancet 373: 1632–1644.
79. Qureshi A. Palesch Y. Martin R. Novitzke J. Cruz S. Ehtisham A. et al (2010) Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage. Arch Neurol 67: 570–576.
80. Raj G. Kumar R. McKinney W. (1999) Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 159: 2721–2724.
81. Refaai M. Phipps R. Spinelli S. Blumberg N. (2011) Platelet transfusions – impact on hemostasis, thrombosis, inflammation, and clinical outcomes. Thromb Res 127: 287–291.
82. Roberts H. Monroe D. White G. (2004) The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 104: 3858–3864.
83. Roquer J. Rodriguez A. Gomis M. Ois A. Puente V. Munteis E. (2005) Previous antiplatelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhage. J Neurol 252: 412–416.
84. Sacco R. Adams R. Albers G. Alberts M. Benavente O. Furie K. et al (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke 37: 577–617.
85. Saloheimo P. Ahonen M. Juvela S. Pyhtinen J. Savolainen E. Hillbom M. (2006) Regular aspirin use preceding the onset of primary inracerebral hemorrhage is an independent predictor for death. Stroke 37: 129–133.
86. Sansing L. Kaznatcheeva E. Perkins C. Komaroff E. Gutman F. Newman G. (2003) edema after intracerebral hemorrhage – correlations with coagulation parameters and treatment. J Neurosurg 98: 985–992.
87. Sansing L. Messe S. Cucchiara B. Cohen S. Lyden P. Kasner S. (2009) Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH. Neurology 72: 1397–1402.
88. Schulman S. Kearon C. Kakkar A. Mismetti P. Schellong S. Eriksson H. et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Eng J Med 361: 2342–2352.
89. Schwab S. Georgiadis D. Berrouschot J. Schellinger P. Graffagnino C. Mayer S. (2001) Feasibility and safety of moderate hypothermia after massive hemispheric infarction. Stroke 32: 2033–2035.
90. Siddique M. Fernandes H. Wooldridge T. Fenwick J. Slomka P. Mendelow A. (2002) Reversible ischemia around intracerebral hemorrhage – a single photon emission computerized tomography study. J Neurosurg 96: 736–741.
91. Silva Y. Leira R. Tejada J. Lainez J. Castillo J. Davalos A. (2005) Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke 36: 86–91.
92. Skolnick B. Mathews D. Khutoryansky N. Pusateri A. Carr M. (2010) Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood 116: 693–701.
93. Sorimachi T. Fujii Y. Morita K. Tanaka R. (2007) Predictors of hematoma enlargement in patients with intracerebral hemorrhage treated with rapid administration of antifibrinolytic agents and strict blood pressure control. J Neurosurg 106: 250–254.
94. Steiner T. Diringer M. Schneider D. Mayer S. Begtrup K. Broderick J. et al (2006 a) Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage - risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery 59: 767–774.
95. Steiner T. Rosand J. Diringer M. (2006 b) Intracerebral hemorrhage associated with oral anticoagulant therapy – current practices and unresolved questions. Stroke 37: 256–262.
96. Stratmann G. de Silva A. Tseng E. Hambleton J. Balea M. Romo A. et al (2004) Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin induced thrombocytopenia. Anesth Analg 98: 1635–1639.
97. Sudlow C. Warlow C. (1997) Comparable studies of the incidence of stroke and its pathological types – results from an international collaboration. Stroke 28: 491–499.
98. Tanaka R. Szlam F. Dickneite G. Levy J. (2008) Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin k antagonist induced anticoagulation. Thromb Res 122: 117–123.
99. Tellez H. Bauer R. (1973) Dexamethasone as treatment in cerebrovascular disease – a controlled study in ICH. Stroke 4: 541–546.
100. Toyoda K. Okada Y. Minematsu K. Kamouchi M. Fujimoto S. Ibayashi S. et al (2005) Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology 65: 1000–1004.
101. Toyoda K. Yasaka M. Nagata K. Nagao T. Gotoh J. Sakamoto T. et al (2009) Antithrombotic therapy influences location, enlargement, and mortality from intracerebral hemorrhage. Cerebrovasc Dis 27: 151–159.
102. van Ryn J. Sieger P. Kink M. Gansser D. Clemens A. (2009) Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro [abstract] New Orleans, LA: American Society of Hematology.
103. van Ryn J. Stangier J. Haertter S. Liesenfeld K. Wienen W. Feuring M. et al (2010) Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103: 1116–1127.
104. Vermeer S. Algra A. Franke C. Koudstaal P. Rinkel G. (2002) Long term prognosis after recovery from primary intracerebral hemorrhage. Neurology 59: 205–209.
105. Vernooij M. van der Lugt A. Ikram M. Wielopolski P. Niessen W. Hofman A. et al (2008) Prevalence and risk factors of cerebral microbleeds – the Rotterdam Study. Neurology 70: 1208–1214.
106. Viswanathan A. Rakich S. Engel C. Snider R. Rosand J. Greenberg S. et al (2006) Antiplatelet use after intracerebral hemorrhage. Neurology 66: 206–209.
107. Wada R. Aviv R. Fox A. Sahlas D. Gladstone D. Tomlinson G. et al (2007) CT angiography spot sign predicts hematoma expansion in acute intracerebral hemorrhage. Stroke 38: 1257–1262.
108. Watson H. Baglin T. Laidlaw S. Makris M. Preston E. (2001) A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 115: 145–149.
109. Yildiz O. Arsava E. Akpinar E. Topcuoglu M. (2011) Previous antiplatelet use is associated with hematoma expansion in patients with spontaneous intracerebral hemorrhage. J Stroke Cerebrovasc Dis 15, June [epub ahead of print].
110. Yu Y. Kumana C. Lauder I. Cheung Y. Chan F. Kou M. et al (1992) Treatment of acute cerebral hemorrhage with intravenous glycerol – a double blind placebo controlled randomized trial. Stroke 23: 967–971.